ArticleArchives of microbiology2026
Selective cytotoxicity of microcin H47 against MDA-MB-231 breast cancer cells: an antimicrobial peptide with therapeutic potential.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer represents a significant therapeutic challenge due to its aggressive behavior and limited treatment options. This study investigates the anticancer potential of microcin H47 (MccH47), a bacteriocin derived from clinical Escherichia coli isolates, against this malignancy. Among 120 screened Enterobacteriaceae isolates, 25 exhibited antimicrobial activity, with isolate 58 confirming MccH47 gene expression through molecular analysis. Cell viability assessment revealed a concentration-dependent reduction in cancer cell survival, while cell death analysis demonstrated approximately 86% apoptosis following 48 h of treatment. Gene expression studies identified significant downregulation of BCL2 and STAT3, indicating involvement of the STAT3/BCL-2 pathway in the observed effects. The extract exhibited biocompatibility toward normal fibroblasts, emphasizing MccH47's dual antimicrobial and antitumor properties with notable therapeutic selectivity. These findings support further development of MccH47 as a novel therapeutic agent for breast cancer treatment.
Indexed as
Identifiers
41677815What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.